Alzforum (Alzheimer Research Forum), 2008-07: Contemporaneous report of the July 2008 ICAD conference presentation in Chicago, where the phase 2 methylene blue results were announced before any peer-reviewed publication existed; it records the dose arms and the fact that results were shown by severity subgroup rather than for the whole cohort.
The company conducted a Phase 2 study randomizing 321 people with mild or moderate AD to treatment with either placebo or one of three oral doses of MTC: 30 mg, 60 mg, or 100 mg three times a day.
Alzforum (Alzheimer Research Forum), 2008-07: Contemporaneous report of the July 2008 ICAD conference presentation in Chicago, where the phase 2 methylene blue results were announced before any peer-reviewed publication existed; it records the dose arms and the fact that results were shown by severity subgroup rather than for the whole cohort. Study type: news.
